0

539730

FREDUN

img img img img
No Data Available

Fredun Pharmaceuticals Limited Share Price Update

As of the latest trading session, Fredun Pharmaceuticals Limited is trading at ₹2100.85, up by ₹61.60 or 3.02% from its previous close. The stock has moved between ₹2070.00 and ₹2200.00 today. Over the past year, the stock has delivered a return of 190.38%. In the last month, it has returned 20.39%.

Investment Returns

Over 1 Month 20.39% Over 3 Months 37.05% Over 6 Months 18.33% Over 1 Year 190.38%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

Fredun Pharmaceuticals Limited fundamentals


  • Market cap (Cr) [-]
  • P/E Ratio (TTM) [-]
  • Beta [-]
  • Book Value / share [-]
  • Return on equity [-]%
  • EPS (TTM) [-]
  • Dividend yield [-]%
  • Net profit/quarter (Cr) [-]
info icon alternate text
  • Market cap (Cr) 1,157.70
  • P/E Ratio (TTM) 33.02
  • Beta 0.48
  • Book Value / share 465.19
  • Return on equity 14.34%
  • EPS (TTM) 61.76
  • Dividend yield [-]%
  • Net profit/quarter (Cr) 10.48
info icon alternate text

Fredun Pharmaceuticals Limited Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars DEC 2025 (Values in Cr)
Revenue 159.93
Operating Expense 146.92
Net Profit 10.48
Net Profit Margin (%) 6.55
Earnings Per Share (EPS) 22.19
EBITDA 26.33
Effective Tax Rate (%) 25.14
Particulars SEP 2025 (Values in Cr)
Revenue 143.59
Operating Expense 132.28
Net Profit 9.73
Net Profit Margin (%) 6.77
Earnings Per Share (EPS) 20.61
EBITDA 22.34
Effective Tax Rate (%) 25.13
Particulars JUN 2025 (Values in Cr)
Revenue 119.40
Operating Expense 110.81
Net Profit 6.77
Net Profit Margin (%) 5.67
Earnings Per Share (EPS) 14.33
EBITDA 16.99
Effective Tax Rate (%) 25.11
Particulars MAR 2025 (Values in Cr)
Revenue 165.44
Operating Expense 159.37
Net Profit 7.07
Net Profit Margin (%) 4.27
Earnings Per Share (EPS) 14.98
EBITDA 17.43
Effective Tax Rate (%) 12.06
Particulars DEC 2024 (Values in Cr)
Revenue 101.84
Operating Expense 95.56
Net Profit 5.33
Net Profit Margin (%) 5.23
Earnings Per Share (EPS) 11.29
EBITDA 13.21
Effective Tax Rate (%) 25.24
Particulars MAR 2025 (Values in Cr)
Revenue 451.71
Operating Expense 428.00
Net Profit 20.81
Net Profit Margin (%) 4.60
Earnings Per Share (EPS) 44.83
EBITDA 55.10
Effective Tax Rate (%) 26.38
Particulars MAR 2024 (Values in Cr)
Revenue 346.58
Operating Expense 327.62
Net Profit 15.62
Net Profit Margin (%) 4.50
Earnings Per Share (EPS) 33.32
EBITDA 38.90
Effective Tax Rate (%) 27.17
Particulars MAR 2023 (Values in Cr)
Revenue 274.34
Operating Expense 258.99
Net Profit 10.81
Net Profit Margin (%) 3.94
Earnings Per Share (EPS) 22.93
EBITDA 29.59
Effective Tax Rate (%) 38.26
Particulars MAR 2022 (Values in Cr)
Revenue 221.74
Operating Expense 217.48
Net Profit 6.34
Net Profit Margin (%) 2.85
Earnings Per Share (EPS) 14.29
EBITDA 15.43
Effective Tax Rate (%) 26.27
Particulars MAR 2021 (Values in Cr)
Revenue 131.55
Operating Expense 130.92
Net Profit 2.01
Net Profit Margin (%) 1.52
Earnings Per Share (EPS) 5.05
EBITDA 9.37
Effective Tax Rate (%) 37.07
Particulars MAR 2024 (Values in Cr)
Book Value / Share 255.15
ROE % 14.34
ROCE % 16.95
Total Debt to Total Equity 0.88
EBITDA Margin 11.17
Particulars MAR 2023 (Values in Cr)
Book Value / Share 194.27
ROE % 13.15
ROCE % 17.43
Total Debt to Total Equity 0.85
EBITDA Margin 10.78
Particulars MAR 2022 (Values in Cr)
Book Value / Share 153.07
ROE % 11.41
ROCE % 12.90
Total Debt to Total Equity 0.83
EBITDA Margin 6.91
Particulars MAR 2021 (Values in Cr)
Book Value / Share 107.96
ROE % 4.76
ROCE % 9.34
Total Debt to Total Equity 0.88
EBITDA Margin 7.16
Particulars MAR 2020 (Values in Cr)
Book Value / Share 103.57
ROE % 4.73
ROCE % 10.16
Total Debt to Total Equity 0.67
EBITDA Margin 7.85
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 1.35
Total Assets 307.59
Total Liabilities 307.59
Total Equity 121.47
Share Outstanding 0
Price to Book Ratio 2.81
Return on Assets (%) 5.07
Return on Capital (%) 6.88
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 3.43
Total Assets 257.27
Total Liabilities 257.27
Total Equity 96.37
Share Outstanding 0
Price to Book Ratio 4.00
Return on Assets (%) 4.20
Return on Capital (%) 5.91
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2.07
Total Assets 186.98
Total Liabilities 186.98
Total Equity 68.06
Share Outstanding 0
Price to Book Ratio 5.98
Return on Assets (%) 3.38
Return on Capital (%) 5.24
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1.12
Total Assets 161.61
Total Liabilities 161.61
Total Equity 43.07
Share Outstanding 0
Price to Book Ratio 4.29
Return on Assets (%) 1.24
Return on Capital (%) 2.44
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 3.05
Total Assets 141.37
Total Liabilities 141.37
Total Equity 41.32
Share Outstanding 0
Price to Book Ratio 1.13
Return on Assets (%) 1.34
Return on Capital (%) 2.5
Particulars MAR 2024 (Values in Cr)
Net Income 15.62
Cash from Operations -0.43
Cash from Investing -7.63
Cash from Financing 5.99
Net change in Cash -2.08
Free Cash Flow 7.20
Particulars MAR 2023 (Values in Cr)
Net Income 10.75
Cash from Operations -14.40
Cash from Investing -9.40
Cash from Financing 25.17
Net change in Cash 1.36
Free Cash Flow -4.91
Particulars MAR 2022 (Values in Cr)
Net Income 6.31
Cash from Operations -2.38
Cash from Investing -4.14
Cash from Financing 7.46
Net change in Cash 0.94
Free Cash Flow 1.90
Particulars MAR 2021 (Values in Cr)
Net Income 2.01
Cash from Operations 0.16
Cash from Investing -1.38
Cash from Financing -0.71
Net change in Cash -1.93
Free Cash Flow 1.55
Particulars MAR 2020 (Values in Cr)
Net Income 2.34
Cash from Operations -10.61
Cash from Investing -1.49
Cash from Financing 13.72
Net change in Cash 1.59
Free Cash Flow -9.12
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 34.76 15.05 1.80 266.38 23.12 40.44
BLISS GVS PHARMA LTD 273.70 26.17 2.55 2895.44 105.05 277.80
CIPLA LTD 1317.15 22.38 3.23 106397.09 1165.55 1672.20
FERMENTA BIOTECH LIMITED 314.25 10.45 2.36 924.87 252.15 399.00
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 34.76 33.42 4.84 266.38 23.12 40.44
AMRUTANJAN HEALTH CARE LTD. 581.15 29.06 4.91 1680.14 490.00 789.95
ASTRAZENECA PHARMA INDIA LTD. 8576.10 103.07 26.83 21440.25 7630.00 10653.05
BLISS GVS PHARMA LTD 273.70 37.29 2.62 2895.44 105.05 277.80

Fredun Pharmaceuticals Limited shareholding pattern

Holding
51.94%
44.16%
1.06%
2.83%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

Fredun Pharmaceuticals Limited Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
2100.00 2.97 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 2051.40
  • 26 Days 1857.50
  • 10 Days 1988.90
  • 50 Days 1774.30
  • 12 Days 1965.80
  • 100 Days 1678.90
  • 20 Days 1894.00
  • 200 Days 1502.60
2059.75 PIVOT
First Support 2000.50 First Resistance 2098.50 Second Support 1961.75 Second Resistance 2157.75 Third Support 1902.50 Third Resistance 2196.50
RSI 68.44 ADX 48.79 MACD 108.29 Williams % R -27.00 Commodity Channel Index (CCI) 105.83
Date 2026-04-27 Week 7425.00 Same Day 3826.00 Month 4915.00
1 Year 0.49 3 Year 0.57
Over 1 Month
20.39% down
Over 1 Year
190.38% down
Over 3 Months
37.05% down
Over 3 Years
31.77% down
Over 6 Months
18.33% down
Over 5 Years
36.56% down

Fredun Pharmaceuticals Limited Corporate Actions

Dividend date Dividend amount Dividend type Record date Instrument type
23 Sep 2025 0.7 Final 23 Sep 2025 Equity shares
23 Sep 2024 0.7 Final 23 Sep 2024 Equity shares
22 Sep 2023 0.7 Final 22 Sep 2023 Equity shares
16 Sep 2021 0.7 Final 18 Sep 2021 Equity shares
16 Sep 2019 0.65 Final 18 Sep 2019 Equity shares
18 Sep 2018 0.6 Final 21 Sep 2018 Equity shares
20 Sep 2017 0.6 Final 22 Sep 2017 Equity shares
11 Apr 2016 0.6 Interim 13 Apr 2016 Equity shares

Top Gainers

Top Losers

Fredun Pharmaceuticals Limited Share Price

Incorporated in 1987 as a private limited company, Fredun Pharmaceuticals Limited (FPL) was converted into a public limited company in Mar.'94. The Company was promoted by Nariman Medhora and Daulat N Medhora. The promoters initially established D N Pharma, a proprietary firm, for the manufacture and export of pharmaceutical formulations. Since 1993, D N Pharma's operations were phased out in order to switch over the business to FPL.

The Company is well diversified in the business ranging from Formulations to Diagnostics to Consultancy. The Company has an unique range of products, from niche formulations , anti-diabetics to the latest antiretroviral and anti - Hypertensive products. It supplies finished formulations to over 42 Countries globally. It is associated with many Governments of different countries which have also realised the need for robust and consistent healthcare systems.

The Company was set up with the objective of providing facilities for manufacturing and marketing of various pharmaceutical formulations like tablets, capsules, dry-syrups and ointments. It then set up a formulation unit at Palghar (Thane District), Maharashtra, which commenced commercial production in Aug.'94. FPL had been carrying out manufacturing operations on loan licence for reputed pharmaceutical companies like Cipla. It also manufactured for some merchant exporters, including Merind.

In Apr.'96, the company came out with a public issue to register its products in the overseas market for exports; to part-finance the expansion of its business activities and to repay one of the term loans and unsecured loans to reduce the interest burden.

Company is very much optimistic of revival of company's turnover by having excellent export order in hand. Company also in process of registering various drugs with different countires such as Nepal, Tanzaniya, Uganda & Sri Lanka.

In 2013, Company launched 36 new products and filed 60 new products for registration. It launched a herbal dietary supplement in Africa. During 2015, three new granulation departments were introduced to the existing two departments. It launched 19 new products under the Cosmeceuticals OEM Division in 2023. It introduced 14 new products in the pet pharmaceuticals line, with another 36 in the works. It launched 16 products into the Pet Treat and Nutritional Supplement category.

In FY 2024, Company launched over 110 products under the Fredun Gx brand in India, including Anti-Diabetics, Anti-Hypertensives, Anti-biotics & Anti-fungal. During FY 2025 a second Italian Tube Filling Machine and two Automatic Carton Packaging Machines have been installed. Company acquired One Pet Stop Pvt Ltd, adding grooming services and access to over 4,000 pet owners. Fredun launched Freossi Tone+ (for lactation and milk quality) and Freossi Power (for joint health and mobility), targeting livestock like cows, buffaloes, horses, and cattle in 2025.

Parent organization Indian Private
NSE symbol [-]
Founded 1987
stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Fredun Pharmaceuticals Ltd?

Answer Field

Fredun Pharmaceuticals Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 2,100.00 as on Apr 28 2026 03:30 PM.

What is the Market Cap of Fredun Pharmaceuticals Ltd Share?

Answer Field

The market cap of Fredun Pharmaceuticals Ltd for NSE ₹ 0.00 & for BSE ₹ 1,157.70 as on Apr 28 2026 03:30 PM.

What is the 52 Week High and Low of Fredun Pharmaceuticals Ltd?

Answer Field

The 52 Week High and Low of Fredun Pharmaceuticals Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 2,200.00 and ₹ 655.20.

What is 1 year return for Fredun Pharmaceuticals Ltd?

Answer Field

The 1 year returns on the stock has been 190.38%.

What is the P/E Ratio of Fredun Pharmaceuticals Ltd Share?

Answer Field

As on Apr 28 2026 03:30 PM the price-to-earnings (PE) ratio for Fredun Pharmaceuticals Ltd share is 33.02.

What is the PB ratio of Fredun Pharmaceuticals Ltd Share?

Answer Field

As on Apr 28 2026 03:30 PM, the price-to-book (PB) ratio for Fredun Pharmaceuticals Ltd share is 465.19.

How to Buy Fredun Pharmaceuticals Ltd Share?

Answer Field

You can trade in Fredun Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Fredun Pharmaceuticals Ltd Share on Bajaj Broking App?

Answer Field

To buy Fredun Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Fredun Pharmaceuticals Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|